Zepp Health Past Earnings Performance
Past criteria checks 0/6
Zepp Health's earnings have been declining at an average annual rate of -53.8%, while the Electronic industry saw earnings growing at 3.7% annually. Revenues have been declining at an average rate of 36.8% per year.
Key information
-53.75%
Earnings growth rate
-53.16%
EPS growth rate
| Electronic Industry Growth | 15.34% |
| Revenue growth rate | -36.84% |
| Return on equity | -18.68% |
| Net Margin | -15.48% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Zepp Health: A Riskier Bet As Gross Margins Compress (Rating Downgrade)
Summary Zepp Health has shifted from a buy to a neutral rating due to persistent unprofitability and margin concerns. Despite >40% y/y revenue growth in Amazfit, ZEPP faces tough comps and macro headwinds that threaten sustained double-digit expansion. Gross margins remain in the high 30s, ~20 points below Garmin, limiting ZEPP’s scalability and profit potential. With abundant high-quality software bargains available, I see little justification to maintain or add to ZEPP positions. Read the full article on Seeking AlphaInvestors Aren't Entirely Convinced By Zepp Health Corporation's (NYSE:ZEPP) Revenues
With a price-to-sales (or "P/S") ratio of 2x Zepp Health Corporation ( NYSE:ZEPP ) may be sending bullish signals at...Market Participants Recognise Zepp Health Corporation's (NYSE:ZEPP) Revenues Pushing Shares 28% Higher
Despite an already strong run, Zepp Health Corporation ( NYSE:ZEPP ) shares have been powering on, with a gain of 28...Just In: One Analyst Has Become A Lot More Bullish On Zepp Health Corporation's (NYSE:ZEPP) Earnings
Zepp Health Corporation ( NYSE:ZEPP ) shareholders will have a reason to smile today, with the covering analyst making...
GDPR Pressures And AI Health Developments Will Shape Future Markets
Zepp Health's consensus price target has surged, primarily reflecting sharply higher expected revenue growth and a much richer projected valuation multiple, now placing fair value at $60.23. What's in the News Zepp Health issued Q3 2025 revenue guidance of $72–76 million, projecting a 23–35% year-over-year increase from $42.5 million.Zepp Health Corporation (NYSE:ZEPP) Soars 336% But It's A Story Of Risk Vs Reward
Zepp Health Corporation ( NYSE:ZEPP ) shareholders have had their patience rewarded with a 336% share price jump in the...Investors Give Zepp Health Corporation (NYSE:ZEPP) Shares A 29% Hiding
Zepp Health Corporation ( NYSE:ZEPP ) shares have had a horrible month, losing 29% after a relatively good period...
AI-powered T-Rex 3 And Amazfit Releases Will Redefine Future Possibilities
Transition to a high-margin business model and AI-powered product launches likely to enhance profitability and drive significant revenue growth.Zepp Health Corporation (NYSE:ZEPP) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Zepp Health Corporation ( NYSE:ZEPP ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Calculating The Intrinsic Value Of Zepp Health Corporation (NYSE:ZEPP)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Zepp Health fair value estimate is US$0.56 Zepp Health's...Zepp Health Corporation (NYSE:ZEPP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Zepp Health Corporation ( NYSE:ZEPP ) shares are down a considerable 27% in the...Zepp Health Corporation's (NYSE:ZEPP) Price Is Right But Growth Is Lacking After Shares Rocket 30%
The Zepp Health Corporation ( NYSE:ZEPP ) share price has done very well over the last month, posting an excellent gain...Zepp Leaves Investors Guessing With Return To Profits, Tumbling Own-Brand Sales
Summary Zepp returned to profitability in the third quarter for the first time since 2021, as its margins jumped with the development of its own Amazfit brand. The company’s shares initially rose sharply after the report, but then fell even more, as investors worried about a big drop in sales of its own-brand products. Zepp’s latest valuation metrics look ridiculously low, including a forward P/E ratio of just 3.1 and a P/S ratio of 0.14. Read the full article on Seeking AlphaCan Zepp Health Find Its Way Back Up?
Summary Zepp Health has had the most tumultuous two years. The share price plummeted 88%, and revenue is down by almost 50%. At this point, is ZEPP stock worth investing in? Read the full article on Seeking AlphaZepp Health Non-GAAP EPADS of -$0.23, revenue of $165.5M
Zepp Health press release (NYSE:ZEPP): Q2 Non-GAAP EPADS of -$0.23. Revenue of $165.5M (-39.6% Y/Y). Total units shipped in the second quarter 2022 decreased by 45.2% year-over-year to 6.3M, compared with 11.5M in the second quarter of 2021. For the third quarter of 2022, the management of the company currently expects: Net revenues to be between RMB1.2 billion and RMB1.5 billion, compared with RMB1.61 billion in the third quarter of 2021 vs. estimated growth of 23.50% Y/Y.What Does Zepp Health Corporation's (NYSE:ZEPP) Share Price Indicate?
Zepp Health Corporation ( NYSE:ZEPP ), might not be a large cap stock, but it saw a decent share price growth in the...Revenue & Expenses Breakdown
How Zepp Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 259 | -40 | 83 | 45 |
| 30 Sep 25 | 233 | -66 | 76 | 45 |
| 30 Jun 25 | 200 | -78 | 76 | 45 |
| 31 Mar 25 | 181 | -81 | 74 | 45 |
| 31 Dec 24 | 183 | -76 | 71 | 46 |
| 30 Sep 24 | 209 | -39 | 69 | 46 |
| 30 Jun 24 | 237 | -25 | 64 | 44 |
| 31 Mar 24 | 296 | -25 | 68 | 47 |
| 31 Dec 23 | 353 | -31 | 71 | 52 |
| 30 Sep 23 | 417 | -40 | 79 | 56 |
| 30 Jun 23 | 492 | -41 | 85 | 62 |
| 31 Mar 23 | 587 | -49 | 98 | 71 |
| 31 Dec 22 | 614 | -43 | 103 | 77 |
| 30 Sep 22 | 665 | -25 | 103 | 70 |
| 30 Jun 22 | 766 | -16 | 106 | 71 |
| 31 Mar 22 | 924 | 14 | 111 | 80 |
| 31 Dec 21 | 983 | 22 | 110 | 81 |
| 30 Sep 21 | 1,017 | 34 | 103 | 85 |
| 30 Jun 21 | 1,114 | 38 | 111 | 95 |
| 31 Mar 21 | 991 | 26 | 102 | 87 |
| 31 Dec 20 | 986 | 35 | 95 | 82 |
| 30 Sep 20 | 968 | 47 | 86 | 81 |
| 30 Jun 20 | 877 | 63 | 71 | 71 |
| 31 Mar 20 | 861 | 73 | 66 | 67 |
| 31 Dec 19 | 835 | 82 | 62 | 62 |
| 30 Sep 19 | 689 | 67 | 53 | 53 |
| 30 Jun 19 | 603 | 57 | 51 | 45 |
| 31 Mar 19 | 575 | 58 | 47 | 39 |
| 31 Dec 18 | 530 | 16 | 45 | 38 |
| 30 Sep 18 | 462 | 4 | 39 | 33 |
| 30 Jun 18 | 389 | -10 | 30 | 30 |
| 31 Mar 18 | 367 | -22 | 29 | 30 |
| 31 Dec 17 | 315 | 7 | 24 | 24 |
| 30 Sep 17 | 287 | 8 | 24 | 21 |
| 31 Dec 16 | 224 | -2 | 19 | 19 |
| 31 Dec 15 | 138 | -9 | 14 | 9 |
Quality Earnings: ZEPP is currently unprofitable.
Growing Profit Margin: ZEPP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZEPP is unprofitable, and losses have increased over the past 5 years at a rate of 53.8% per year.
Accelerating Growth: Unable to compare ZEPP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZEPP is unprofitable, making it difficult to compare its past year earnings growth to the Electronic industry (12.5%).
Return on Equity
High ROE: ZEPP has a negative Return on Equity (-18.68%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 13:59 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zepp Health Corporation is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ang-Chi Lin | Citigroup Inc |
| Siddharth Rajeev | Fundamental Research Corp. |
| Jones Ku | Haitong International Research Limited |